8-K filing — Vivani Medical, Inc. (VANI)
Filed: 2026-08-17 AccNo: 0001753926-26-001536 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream
EmergingGrowth.com announces the 94th Emerging Growth Conference scheduled for July 15-16, 2026, featuring presentations from 20+ small-cap and emerging growth companies across sectors including mining, technology, healthcare, and renewable energy. The virtual conference allows companies to present their strategies, products, and announcements to the investment community.
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant